Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 198

Similar articles for PubMed (Select 23306941)

2.

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P.

J Hepatol. 2011 May;54(5):866-71. doi: 10.1016/j.jhep.2010.08.024. Epub 2011 Jan 14.

PMID:
21145807
3.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
4.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

5.

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA.

J Infect. 2013 Jul;67(1):59-64. doi: 10.1016/j.jinf.2013.03.010. Epub 2013 Mar 28.

PMID:
23542783
6.

Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ.

J Gastroenterol Hepatol. 2014 Jan;29(1):102-9. doi: 10.1111/jgh.12329.

PMID:
23829453
7.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
8.

Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.

Dogan UB, Akin MS, Yalaki S.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1317-20. doi: 10.1097/MEG.0b013e328362797b.

PMID:
23680912
9.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

PMID:
21443535
10.

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

Scherzer TM, Stättermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, Datz C, Dulic-Lakovic E, Steindl-Munda P, Hofer H, Ferenci P.

Hepatology. 2011 Nov;54(5):1518-26. doi: 10.1002/hep.24546.

PMID:
22006276
11.

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.

Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS.

PLoS One. 2011 Mar 30;6(3):e18322. doi: 10.1371/journal.pone.0018322.

12.

Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.

Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM.

J Viral Hepat. 2010 Feb 1;17(2):139-47. doi: 10.1111/j.1365-2893.2009.01157.x. Epub 2009 Aug 5.

13.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M.

Gastroenterology. 2014 Feb;146(2):430-41.e6. doi: 10.1053/j.gastro.2013.10.058. Epub 2013 Nov 1.

PMID:
24184810
14.

Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.

Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2010 Apr;25(4):758-65. doi: 10.1111/j.1440-1746.2009.06148.x.

PMID:
20492331
15.

Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?

de Segadas-Soares JA, Villela-Nogueira CA, Perez RM, Nabuco LC, Brandão-Mello CE, Coelho HS.

J Clin Gastroenterol. 2009 Apr;43(4):362-6. doi: 10.1097/MCG.0b013e3181775e6a.

PMID:
19077732
16.

[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].

He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):34-7. doi: 10.3760/cma.j.issn.1007-3418.2011.01.010. Chinese.

PMID:
21272456
17.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

AIDS. 2008 Jan 2;22(1):15-21.

PMID:
18090387
18.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
19.
20.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Hepatology. 2008 Jun;47(6):1884-93. doi: 10.1002/hep.22319.

PMID:
18508296
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk